ULTRAGENYX PHARMACEUTICAL INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $3.32 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-27.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2015-11-10
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2014-06-30 was $0.00, a 100.00% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2014-03-31 was $3.32M.
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2014 was $3.32M, a 14.58% increase from fiscal 2013.
- ULTRAGENYX PHARMACEUTICAL INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2013 was $2.90M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $0.00 derived: sum of 3 quarters · filed 2015-11-10 | $3.32M 10-K · filed 2015-03-27 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $0.00 derived: sum of 2 quarters · filed 2015-11-10 | $3.32M 10-Q · filed 2015-11-10 | $5.15M derived: sum of 4 quarters · filed 2015-11-10 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $3.32M 10-Q · filed 2015-08-14 | $5.15M derived: sum of 3 quarters · filed 2015-08-14 | $5.85M derived: sum of 4 quarters · filed 2015-08-14 |
| 2014-03-31 | $3.32M 10-Q · filed 2015-05-12 | $5.15M derived: sum of 2 quarters · filed 2015-05-12 | $5.85M derived: sum of 3 quarters · filed 2015-05-12 | $6.23M derived: sum of 4 quarters · filed 2015-05-12 |
| 2013-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $2.53M derived: sum of 2 quarters · filed 2015-03-27 | $2.90M derived: sum of 3 quarters · filed 2015-03-27 | $2.90M 10-K · filed 2015-03-27 |
| 2013-09-30 | $706.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $1.08M derived: sum of 2 quarters · filed 2014-11-10 | $1.08M 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $374.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $372.00K 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | -$2.00K 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |